1. Home
  2. Companies
  3. TLX
  4. Material Events

Telix Pharmaceuticals (ASX:TLX) — Material Events

ASX:TLX · 23 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 5 articles Significant 17 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
17
Telix Resubmits FDA Application for Brain Cancer Imaging Agent Pixclara®Medium
Telix Resubmits NDA for Brain Cancer Imaging Agent TLX101-Px to FDA with Additional Data
16 Mar 2026 ·Regulatory Update ·85
CMS Boosts Telix’s Gozellix with Key US Reimbursement WinMedium
CMS Grants Reimbursement Status for Telix's Gozellix Prostate Cancer Imaging Agent
23 Sept 2025 ·Regulatory Update ·85
Telix Secures FDA Nod to Expand ProstACT Phase 3 Prostate Cancer TrialMedium
Telix secures FDA alignment to advance ProstACT Global Phase 3 prostate cancer trial
2 July 2026 ·Clinical Trial Update ·85
Telix Reports 11% Q1 Revenue Growth and Advances Prostate Cancer Therapy TrialsMedium
Telix reports strong Q1 revenue growth, advances prostate cancer therapy trials, and reaffirms FY 2026 guidance
7 Apr 2026 ·Quarterly Business Update ·85
Telix Surges with $204M Q2 Revenue, Launches Gozellix Amid SEC InquiryHigh
Telix Reports $204M Q2 Revenue, Launches Gozellix in U.S., Advances Clinical Trials, SEC Inquiry Disclosed
22 July 2025 ·Quarterly Financial and Operational Update ·85
Telix Advances Brain Cancer Imaging with European Filing for TLX101-PxMedium
Telix Submits European Marketing Authorization Application for Brain Cancer Imaging Agent TLX101-Px
18 Feb 2026 ·Regulatory Filing ·85
FDA Accepts Telix’s NDA for Glioma Imaging Agent TLX101-Px with September Review TargetHigh
FDA Accepts NDA for Telix's Glioma Imaging Agent TLX101-Px with Approval Target in September 2026
10 Apr 2026 ·Regulatory Update ·85
Telix Pharmaceuticals Posts 63% Revenue Surge Amid Strategic Expansion and SEC InquiryHigh
Telix reports 63% revenue growth but posts $2.3M H1 net loss amid expansion and SEC inquiry
21 Aug 2025 ·Appendix 4D and Interim Report ·Unexpected ·85
Telix Scores Regulatory Nod to Bring Illuccix Prostate Imaging to ChinaMedium
Telix's Illuccix NDA accepted by Chinese regulator, backed by positive Phase 3 data
20 Jan 2026 ·Regulatory Announcement ·85
Telix Advances ProstACT Phase 3 Trial with First Patient Dosed in Global ExpansionMedium
Telix Doses First Patient in Expanded Phase 3 ProstACT Trial for Prostate Cancer
8 Dec 2025 ·Clinical Trial Update ·85
Telix Launches US$550 Million Convertible Bonds to Refinance Debt and Fund GrowthMedium
Telix Pharmaceuticals launches US$550 million convertible bonds offering to refinance existing debt
14 Apr 2026 ·Capital Raising ·85
Telix Advances With Strong Illuccix Data and FDA Resubmission ProgressMedium
Telix reports positive Illuccix China Phase 3 data and FDA resubmission progress for TLX101-CDx and TLX250-CDx
22 Dec 2025 ·Clinical Trial Update and Regulatory Filing Update ·85
Telix’s ProstACT Phase 3 Part 1 Confirms Safety, Paving Way for Global ExpansionMedium
Telix's ProstACT Phase 3 Part 1 meets safety goals; Part 2 enrollment underway globally
10 Mar 2026 ·Clinical Trial Update ·85
Telix Powers Ahead with 63% Revenue Surge and Pipeline MilestonesMedium
Telix reports 63% revenue growth in H1 2025, boosts R&D investment, confirms FY guidance
21 Aug 2025 ·Half-Year Results Announcement ·85
Telix Advances ProstACT Phase 3 Prostate Cancer Trial to Part 2 with Global ApprovalsMedium
Telix Advances ProstACT Phase 3 Prostate Cancer Trial to Part 2 with Global Regulatory Approvals
17 Dec 2025 ·Clinical Trial Update ·80
Telix Faces FDA Setback on TLX250-CDx but Eyes Swift ResolutionHigh
Telix Receives FDA Complete Response Letter for TLX250-CDx; Plans Remediation and Maintains 2025 Guidance
28 Aug 2025 ·Regulatory Update ·Unexpected ·75
Telix and FDA Align on Resubmission for TLX101-CDx with Expedited Review ExpectedMedium
Telix and FDA agree on NDA resubmission plan for TLX101-CDx with likely expedited review
9 Sept 2025 ·Regulatory Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.